Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 524322 | NSE Symbol : | ISIN : INE323K01017 | Industry : Pharmaceuticals - Indian - Formulations |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
07-Aug-2025	14-Aug-2025	Quarterly Results	Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2025 inter alia to consider and approve Intimation of Board Meeting
31-Jul-2025	06-Aug-2025	Expansion	Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2025 inter alia to consider and approve Board Meeting on 6 August 2025 Outcome of the Board Meeting and disclosure under Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on: 06.08.2025)
09-Jun-2025	18-Jun-2025	Acquisitions	Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/06/2025 inter alia to consider and approve This is to inform you that a meeting of the Board of Directors of the Company will be held on Wednesday June 18 2025 at 5:00 PM in Companys Chennai Office to take on record the following matter: 1. New acquisition 2. New drug license for a Chennai office 3. Diversification by creating new subsidiary 4. Any other agenda with the permission of the chair Outcome of the Board Meeting and disclosure under Regulation 30 of SEBI(Listing Obligations & Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement dated on 18.06.2025)
23-May-2025	30-May-2025	Accounts	Kabra Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 inter alia to consider and approve 1. To consider and approve the audited financial results for the quarter and the year ended on 31st March 2025 pursuant to regulation 33 of SEBI (Listed Obligations and Disclosure Requirements) Regulations 2015; 2. To consider any other matter with the permission of the Chairman of the meeting. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 30th May 2025, inter-alia, considered and approved (As Per BSE Announcement Dated on: 30/05/2025)
07-Feb-2025	14-Feb-2025	Quarterly Results	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2025 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company to be held on Friday 14th February 2025 at Registered Office at 05.00 p.m. to transact the business as given below: 1.To consider and approve Unaudited financial results for the quarter ending on 31st December 2024 along with Limited Review Report pursuant to regulation 33 of SEBI (Listed Obligations and Disclosure Requirements) Regulations 2015; 2.To consider any other matter with the permission of the Chairman of the meeting. With reference to the above captioned subject, we hereby informed you that the Board of Directors at their meeting held today i.e., 14th February 2025, Board Meeting commenced at 05:00 PM. concluded at 6:30 PM at the registered office of the company have considered and approved the following: (As Per Bse Announcement Dated on 14.02.2025)
25-Nov-2024	04-Dec-2024	Raising funds through Debt Instr.	Inter alia to consider and approve the following matters: 1. To consider and approve proposal of fund raising by issue of equity shares or any other permitted mode, through Preferential Allotment/Private Placement / Convertible warrants basis to the Promoter /Non-Promoter / Public Category of investors in accordance with the provision of the Companies Act, 2013 and SEBI (Issue of Capital and Disclosure Requirements Regulation, 2018, as amended, subject to regulatory or statutory approvals as may be required including the approval of the shareholders of the Company. 2. Increase in Authorised Share Capital of the company from 2,00,00,000 shares to 3,00,00,000 of Rs. 10 each. 3. To Consider shifting of Registered office of the company from Shop 208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh 452011to No.3, 1st Floor, Swaminathan Street, West Mambalam, Chennai - In Compliance of Regulation 30 of the SEBI (LODR) Regulations, 2015 - Outcome of Board Meeting held on December 4, 2024. (As per BSE Announcement Dated on 04/12/2024)
07-Nov-2024	14-Nov-2024	Quarterly Results	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday 14th November 2024 at 5 PM in our Registered office to transact the business Unaudited Financial Result for the quarter and half year ended September 30, 2024 Under Regulation 33 of SEBI (LODR) Regulations, 2015 (As per BSE Announcement dated on 14/11/2024)
21-Oct-2024	04-Nov-2024	Raising funds through Debt Instr.	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2024 inter alia to consider and approve Board of Directors of Company will be held on Monday November 04 2024 at 5.00 P.M. to consider and evaluate proposal for raising of funds by the Company Out come of Board Meeting (As per BSE Announcement Dated on 04/11/2024)
27-Aug-2024	02-Sep-2024	AGM	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2024 inter alia to consider and approve Notice is hereby given that a meeting of the Board of Directors of the Company will be held on Monday September 2nd 2024 at 5:00 PM to consider and approve. Board of Directors of the company was held today viz Monday, 2nd September 2024 at registered office at 5:00 P.M. and concluded at 8:00 P.M. (As Per BSE Announcement Dated on: 02/09/2024)
07-Aug-2024	14-Aug-2024	Quarterly Results	Quarterly Results Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 14th August 2024, (As per BSE Announcement Dated on 14/08/2024)
06-Jul-2024	12-Jul-2024	Change in Registered Address	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/07/2024 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company in convened on Friday 12 July 2024 at 03.00 p.m. to transact the business as given below: 1. To consider and change the registered office of the Company within the local limits of city where the registered office of the company is presently situated; 2. To consider any other matter with the permission of the Chairman of the meeting. Note: The trading window for dealing in shares in the Company for all the promoters directors designated employees and the concerned connected persons has been closed till 48 hours of the announcement of the financial results. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 12th July 2024, inter-alia, considered and approved the following: 1. The Registered Office of the Company is shifted from 270 Shastri Market Indore, Indore, Indore, Madhya Pradesh, India, 452007' to '208, Swadesh Bhavan, 2 Press Complex, AB Road, Indore, Madhya Pradesh 452011. 2. The Corporate office of the Company where books of accounts are maintained is No.3, 2nd Floor, Swaminathan Street, West Mambalam, Chennai, Tamil Nadu, 600033. The meeting of the Board of Directors of the Company commenced at 03.00 p.m. (IST) and concluded at 05:00 p.m. (IST). (As per BSE Announcement Dated on 12/07/2024)
05-Jul-2024	05-Jul-2024	Preferential Issue	With regards to the captioned matter and pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that at the meeting of the Board of Directors of Kabra Drugs Limited held today i.e. Friday, July 5, 2024 at 5:15 P.M. and concluded at 6:00 P.M. at the registered office of the Company situated at Office no: Shop No. 270, Shastri Market, Indore, Madhya Pradesh, 452001. It discussed and approved the matter with respect to the issuance of 56,90,500 equity shares of face value Rs.10/- each of the Company to non-promoters on preferential basis under Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
22-May-2024	30-May-2024	Accounts	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2024 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company in convened on Thursday 30th May 2024 at registered office at 05.00 p.m. to transact the business as given below: 1. To consider and approve the audited financial results for the quarter and the year ended on 31st March 2024 pursuant to regulation 33 of SEBI (Listed Obligations and Disclosure Requirements) Regulations 2015; 2. To consider any other matter with the permission of the Chairman of the meeting. Note: The trading window for dealing in shares in the Company for all the promoters directors designated employees and the concerned connected persons has been closed till 48 hours of the announcement of the financial results. Pursuant to the provisions of Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that the Board of Directors of the Company at its meeting held today i.e 30th May 2024, inter-alia, considered and approved the following: 1. Audited financial results for the quarter and the year ended 31st March, 2024 along with Independent Auditors Report 2. The Board discussed the compliance of the Statement of Deviation or Variation as per the Regulation 32 of SEBI (LODR) Regulations, 2015 and is of the view that the same is not applicable to company as the company has not issued any share by way of Public Issue, Right Issue, Preferential Issue etc. The undertaking of non-applicability of Regulation 32 of SEBI (LODR) Regulations, 2015 is enclosed herewith. 3. Appointment of Secretarial Auditor: Appointed as Secretarial Auditor of the Company to conduct Secretarial audit for the Financial Year 2023-24. Read less.. Appointment of Secretarial Auditor (As Per BSE Announcement Dated on 30.05.2024)
05-Feb-2024	14-Feb-2024	Quarterly Results	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2024 inter alia to consider and approve This is to inform you that the meeting of the Board of Directors of the Company to be held on Wednesday 14th February 2024 at Registered Office at 04.00 p.m. to transact the business as given below: 1. To consider and approve Unaudited financial results for the quarter ending on 31st December 2023 along with Limited Review Report pursuant to regulation 33 of SEBI (Listed Obligations and Disclosure Requirements) Regulations 2015; 2. To consider any other matter with the permission of the Chairman of the meeting. Note: The trading window for dealing in shares of the Company for all the promoters directors designated employees and the concerned connected persons has been closed till 48 hours of the announcement of the financial results. With reference to the above captioned subject, we hereby informed you that the Board of Directors at their meeting held today i.e., Wednesday, 14th February 2024, 04:00 PM. concluded at 4:30 PM at the registered office of the company have considered and approved the following: (As Per BSE Announcement Dated on: 14/02/2024)
18-Jan-2024	23-Jan-2024	Preferential Issue	KABRA DRUGS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/01/2024 inter alia to consider and approve We are pleased to inform you that the meeting of the Board of Directors of KABRA DRUGS LIMITED is scheduled to be held on Tuesday i.e. January 23 2024 at the Registered office of the Company situated at Shop No. 270 Shastri Market Indore Madhya Pradesh 452001 India. inter alia to consider and approve the following matters: To consider and approve proposal of fund raising by issue of equity shares or any other permitted mode through Preferential Allotment/Private Placement basis to the Non-Promoter / Public Category of investors in accordance with the provision of the Companies Act 2013 and SEBI (Issue of Capital and Disclosure Requirements Regulation 2018 as amended subject to regulatory or statutory approvals as may be required including the approval of the shareholders of the Company. Increase in Authorised Share Capital of the company from Rs.5 crores to Rs.16 Crores. Any other matter with permission of the Chairman. With regards to the captioned matter and pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we wish to inform you that at the meeting of the Board of Directors of Kabra Drugs Limited held today i.e. Tuesday, January 23, 2024 commenced at 5.00 pm at the Registered office of the Company situated at Shop No. 270, Shastri Market, Indore, Madhya Pradesh - 452 001, India. The Board of Directors of the Company ('Board') considered, deliberated and discussed, approved / noted the following matters: (As per BSE Announcement Dated on 23/01/2024) Revised Outcome of Board Meeting held on January 23, 2024 (As Per BSE Announcement Dated on 24/01/2024)

1 2 3

LOGIN HERE

Kabra Drugs Ltd

Board Meeting